A methodology of drug development by Physiotarget® to assist the chemotherapy of solid and liquid tumors
What is Genochem®?
– Genochem® is a registered pharmacogenomics brand of Physiotarget®.
– Genochem® is being developed as a complement to Terafen®.
– Oncotargets, as defined under Terafen®, do not depend on mutation, but rather on gene expression. Accordingly, Genochem® seeks to support the development of the best drugs against these oncotargets.
– The purpose of Genochem® is to apply our pipeline to select the best druggable protein targets in the signaling network for personalized oncological treatment.
– Genochem® uses fundamental properties of signaling networks to prioritize the best oncotarget through mixed AI and computational methods.
– Genochem® also aims to use the computational biology toolbox for drug repurposing against oncotargets in solid and liquid tumors.
What Genochem® is not?
– Genochem® does not validate ligands in vitro or in vivo; this process is performed in collaboration with specialized teams. Genochem® limits its activities to in silico inferences.
– Since the business model of Physiotarget® is to license technologies and collaborate with pharmaceutical industries and hospitals, Genochem® does not intend to cover all drug development activities but rather to limit itself to contributing to drug development through in silico methods.
What is the difference between Genochem® and other methods?
– The approach of Genochem®, together with Terafen®, is based on proprietary methodologies, all of which are being published in peer-reviewed journals
When is the use of Genochem® indicated?
– Genochem® aims to assist in the development of affordable drugs where no approved solution is available yet.
For more information, send us a message at physiotarget@physiotarget.com